BioPharma Resources

Drug Trial Radar · NCT05096208

Clinical Lot Consistency for RSVpreF in a Population of Healthy Adults 18 to ≤49 Years of Age

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF 3 LOTS OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN HEALTHY ADULTS

Last checked: Nov 19, 2026Latest source record: Apr 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,028 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,028

Actual

Start

Oct 21, 2021

Primary completion

Apr 4, 2022

Study completion Apr 4, 2022

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Oct 27, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 49 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This randomized, double-blinded, placebo-controlled Phase 3 study is designed to evaluate the safety, tolerability, and immunogenicity of 3 lots of RSVpreF in healthy adults.

Conditions

  • RSV

Interventions

  • RSVpreF (Group 1)Biological

    RSV vaccine (RSVpreF)

  • RSVpreF (Group 2)Biological

    RSV vaccine (RSVpreF)

  • RSVpreF (Group 3)Biological

    RSV vaccine (RSVpreF)

  • PlaceboBiological

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Geometric Mean Ratios (GMRs) of Respiratory Syncytial Virus Subgroup A (RSV A) and B (RSV B) Neutralizing Antibodies at 1 Month After Vaccination for Every Pair of RSVpreF LotsTime frame: 1 month (27 to 42 days window) after vaccination on Day 1
  2. Percentage of Participants With Local Reactions Within 7 Days After VaccinationTime frame: Within 7 days after vaccination on Day 1
  3. Percentage of Participants With Systemic Events Within 7 Days After VaccinationTime frame: Within 7 days after vaccination on Day 1
  4. Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Day of consent (Day 1) through study completion (approximately 1 Month)

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Global Health Research Center, Inc.

    Miami Lakes, Florida

  • Precision Clinical Research

    Sunrise, Florida

  • Clinical Site Partners, Inc

    Winter Park, Florida

  • Clinical Site Partners

    Winter Park, Florida

  • Clinical Research Atlanta

    Stockbridge, Georgia

  • East-West Medical Research Institute

    Honolulu, Hawaii

  • Clinical Research Prime

    Idaho Falls, Idaho

  • Kentucky Pediatric/ Adult Research

    Bardstown, Kentucky

  • Sundance Clinical Research

    St Louis, Missouri

  • Meridian Clinical Research, LLC

    Omaha, Nebraska

  • Accellacare - Wilmington

    Wilmington, North Carolina

  • Aventiv Research Inc

    Columbus, Ohio

  • Velocity Clinical Research, Providence

    East Greenwich, Rhode Island

  • Benchmark Research

    Austin, Texas

  • Texas Center for Drug Development, Inc.

    Houston, Texas

  • DM Clinical Research

    Tomball, Texas

  • J. Lewis Research, Inc. / Foothill Family Clinic

    Salt Lake City, Utah

  • J. Lewis Research, Inc. / Foothill Family Clinic South

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.